___

• Kaynaklar 1.Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalen-ce of atopic dermatitis in Oregon school children. J Am AcadDermatol 2000; 43: 649–655. 2.Tamburro J. Dermatology for the pediatrician: Advances in di-agnosis and treatment of common and not-so-common skin con-ditions. Cleve Clin J Med 2015; 82 (11 Suppl 1): S19-23. 3.Hanifin JM, Reed ML; Eczema Prevalence and Impact Wor-king Group. A population-based survey of eczema prevalen-ce in the United States. Dermatitis 2007; 18: 82–91. 4.Ruzicka T. Atopic eczema between rationality and irrationa-lity. Arch Dermatol 1998; 134: 1462–69. 5.Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitiza-tion through barrier-disrupted skin elicits a TH2-dominant cyto-kine response. Eur J Immunol 1998; 28: 769–79. 6.Hon KL, Leung AK, Barankin B. Barrier repair therapy in ato-pic dermatitis: an overview. Am J Clin Dermatol 2013; 14:389–99. 7.Halken S. Prevention of allergic disease in childhood: clini-cal and epidemiological aspects of primary and secondary al-lergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl16): 4–5, 9–32. 8.Marini A, Agosti M, Motta G, Mosca F. Effects of a dietaryand environmental prevention programme on the incidenceof allergic symptoms in high atopic risk infants: three years’follow-up. Acta Paediatr Suppl 1996; 414: 1–21. 9.Admani S, Jacob SE. Allergic contact dermatitis in children:review of the past decade. Curr Allergy Asthma Rep 2014; 14:421. 10.Holme SA, Stone NM, Mills CM. Toilet seat contact derma-titis. Pediatr Dermatol 2005; 22: 344–45. 11.Heilig S, Adams DR, Zaenglein AL. Persistent allergic con-tact dermatitis to plastic toilet seats. Pediatr Dermatol 2011;28: 587–90. 12.Litvinov IV, Sugathan P, Cohen BA. Recognizing and treatingtoilet-seat contact dermatitis in children. Pediatrics 2010; 125:e419–e422. 13.Castanedo-Tardana MP, Zug KA. Methylisothiazolinone.Dermatitis 2013; 24: 2–6. 14.Ghali FE. “Car seat dermatitis”: a newly described form ofcontact dermatitis. Pediatr Dermatol 2011; 28: 321–26. 15.Herro E, Jacob SE. p-tert-Butylphenol formaldehyde resin andits impact on children. Dermatitis 2012; 23: 86–88. 16.Malajian D, Belsito DV. Cutaneous delayed-type hypersen-sitivity in patients with atopic dermatitis. J Am Acad Derma-tol 2013; 69: 232–37. 17.Foster KW, Ghannoum MA, Elewski BE. Epidemiologic sur-veillance of cutaneous fungal infection in the United States from1999 to 2002. J Am Acad Dermatol 2004; 50: 748–52. 18.Gupta AK, Drummond-Main C. Meta-analysis of randomized,controlled trials comparing particular doses of griseofulvinand terbinafine for the treatment of tinea capitis. Pediatr Der-matol 2013; 30: 1–6. 19.Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angio-genesis via down-regulating the expression of vascular endot-helial growth factor in hemangioma derived stem cell. Int JClin Exp Pathol 2013; 7: 48–55. 20.Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and useof propranolol for infantile hemangioma: report of a consen-sus conference. Pediatrics 2013; 131: 128–40. 21.Tollefson MM, Frieden IJ. Early growth of infantile heman-giomas: what parents’ photographs tell us. Pediatrics 2012;130: e314–e320. 22.Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ. Earlywhite discoloration of infantile hemangioma: a sign of impen-ding ulceration. Arch Dermatol 2010; 146: 1235–39. 23.Lenane P, Macarthur C, Parkin PC, et al. Clobetasol propio-nate, 0.05%, vs hydrocortisone, 1%, for alopecia areata inchildren: a randomized clinical trial. JAMA Dermatol 2014;150: 47–50. 24.Lim YH, Ovejero D, Sugarman JS, et al. Multilineage soma-tic activating mutations in HRAS and NRAS cause mosaic cu-taneous and skeletal lesions, elevated FGF23 and hypophosp-hatemia. Hum Mol Genet 2014; 23: 397–407. 25.Koenig MK, Hebert AA, Roberson J, et al. Topical rapamy-cin therapy to alleviate the cutaneous manifestations of tube-rous sclerosis complex: a double-blind, randomized, control-led trial to evaluate the safety and efficacy of topically app-lied rapamycin. Drugs R D 2012; 12: 121–26.